Website value calculator & SEO Checker => iconplc.com

Q: What IP iconplc.com has?

The domain iconplc.com has IP 3.248.119.236 . An IP address is a string of numbers used to make devices accessible for communication.

SEO report with information and free domain appraisal for iconplc.com. It is a domain hosted in . Its server is hosted on IP 3.248.119.236. The domain is ranked at the number 125531 as a world ranking of web pages. According to estimated data we have access to potential gains of this site are 494 dollars per month. In annual terms, the domain iconplc.com could be earning more than 5923 dollars. If someone wanted to buy the domain a good selling price would be 59229 dollars.

These data are estimated and can not be taken as 100 % real. Only give an estimate of profits depending on the subject and the traffic generated by iconplc.com . The estimated number of unique visitors accessing iconplc.com is 4313. Thus the total number of people who visit this page per month would be 129378 people.

Domain Authority

SEO Score

☰ Report Resume

SEO score
Speed
Page Load Time
Current Ip of the domain: 3.248.119.236
Charset of page: UTF-8
Total Keywords: 1123
Total Links:

Anchor text
Type
Link

follow

follow
/
Services
follow
/services/
Read More
follow
/services/
Services
follow
/services/
Clinical Research Services
follow
/services/clinical-research-services/
Commercial Positioning
follow
/services/consulting/commercial-positioning-consulting/
Consulting
follow
/services/consulting/
Early Phase
follow
/services/early-phase/
Functional Services Provision
follow
/services/functional-services-provision/
Laboratories
follow
/services/laboratories/
Language Services
follow
/services/language-services/
Medical Imaging
follow
/services/imaging/
Real World Intelligence
follow
/services/real-world-intelligence/
Site & Patient Solutions
follow
/services/clinical-research-services/site-and-patient-recruitment/
COVID-19 clinical operationsClinical trials during COVID-19.
follow
/services/clinical-research-services/covid-19/
Decentralised & hybrid clinical solutionsBringing the clinical trial to the patient with innovation and in-home solutions.
follow
/services/clinical-research-services/decentralised-and-hybrid-clinical-solutions/
Sectors
follow
/sectors/
Read More
follow
/sectors/
Sectors
follow
/sectors/
Biosimilars
follow
/sectors/biosimilars/
Biotech
follow
/sectors/biotech/
Government & Public Health Solutions
follow
/sectors/government-and-public-health-solutions/
Medical Device
follow
/sectors/medical-device/
Pharmaceuticals
follow
/sectors/pharma/
The IVDR journeyA roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
follow
/insights/regulatory/eu-regulations/the-ivdr-journey/
BiotechDeveloping transformative therapies requires a flexible approach.
follow
/sectors/biotech/
Therapeutics
follow
/therapeutics/
Read More
follow
/therapeutics/
Therapeutics
follow
/therapeutics/
Cardiovascular
follow
/therapeutics/cardiovascular/
Cell and Gene Therapies
follow
/therapeutics/cell-and-gene-therapies/
Central Nervous System
follow
/therapeutics/central-nervous-system/
Endocrine & Metabolic Disorders
follow
/therapeutics/endocrine-metabolic-disorders/
Infectious Diseases
follow
/therapeutics/infectious-diseases/
Internal Medicine & Immunology
follow
/therapeutics/internal-medicine-and-immunology/
Medical Device
follow
/therapeutics/medical-device/
Oncology
follow
/therapeutics/oncology/
Paediatrics
follow
/therapeutics/paediatrics/
Rare & Orphan Diseases
follow
/therapeutics/rare-and-orphan-diseases/
Transplant Immunology
follow
/therapeutics/transplant-immunology/
Women"s Health
follow
/therapeutics/womens-health/
VaccinesICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
follow
/therapeutics/vaccines/
Therapeutics insightsICON"s therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
follow
/insights/therapeutics/
Innovation
follow
/innovation/
Read More
follow
/innovation/
Innovation
follow
/innovation/
ADDPLAN®
follow
/innovation/addplan/
FIRECREST
follow
/innovation/firecrest/
Safety Reporting Solution
follow
/innovation/drug-safety-reporting-solution/
One Search
follow
/innovation/one-search/
Evidence Platform
follow
/innovation/evidence-platform/
FLEX ADVANTAGE
follow
/innovation/flex-advantage/
Medical Imaging Technology
follow
/innovation/imaging-technology/
NONMEM
follow
/innovation/nonmem/
ICONIK
follow
/innovation/ICONIK/
PDx-POP
follow
/innovation/pdx-pop/
PubsHub
follow
/innovation/pubshub/
SIMS
follow
/innovation/sims/
FIRECRESTWith travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
follow
/innovation/firecrest/
Patient Engagement PlatformConnecting patients with the right trial in the right location.
follow
/innovation/patient-engagement-platform/
Insights
follow
/insights/
Read More
follow
/insights/
Insights
follow
/insights/
Digital Disruption
follow
/insights/digital-disruption/
Patient Centricity
follow
/insights/patient-centricity/
Regulatory Intelligence
follow
/insights/regulatory/
Therapeutics insights
follow
/insights/therapeutics/
Transforming Trials
follow
/insights/transforming-trials/
Value Based Healthcare
follow
/insights/value-based-healthcare/
Blog
follow
/insights/blog/
Videos
follow
/insights/videos/
Webinar Channel
follow
https://webinars.iconplc.com/
Early engagement and regulatory considerations for biotechThe importance of regulatory strategy
follow
/insights/regulatory/regulatory-considerations-for-biotech/
Decentralised & hybrid clinical trialsPatient focused research for better outcomes.
follow
/insights/transforming-trials/decentralised-and-hybrid-clinical-trials/
News & Events
follow
/news-events/
Read More
follow
/news-events/
News & Events
follow
/news-events/
Press releases
follow
/news-events/press-releases/
In the News
follow
/news-events/thought-leadership/
Mediakit
follow
/news-events/mediakit/
Awards
follow
/news-events/awards/
Events
follow
/news-events/events/
Webinars
follow
/news-events/events/webinars/
Social media
follow
/news-events/social-media/
Financial Times Global Pharmaceutical and Biotechnology Conference8 – 10 November, 2021 Online event
follow
/news-events/events/industry-events/financial-times-global-pharmaceutical-biotechnology-conference-2021/
ICON’s world children’s dayNovember 15, 2021. Register now.
follow
/news-events/events/webinars/icons-world-childrens-day/
About ICON
follow
/about/
Read More
follow
/about/
About ICON
follow
/about/
Company history
follow
/about/company-history/
ICON in Asia Pacific
follow
/about/icon-in-asia-pacific/
ICON in Latin America
follow
/about/icon-in-latin-america/
Leadership
follow
/about/leadership/executive-management/
Quality
follow
/about/our-quality/
Environmental, Social & GovernanceICON is committed to making a positive impact on our people, environment and our community.
follow
/about/esg/
ICON and YouPartners making a difference.
follow
/about/icon-and-you/
Careers
follow
/careers/
Investors
follow
http://investor.iconplc.com/
Investigators
follow
/investigators/
Patients
follow
https://www.accellacare.com/
Contact
follow
/contact/
EN
follow
/?Language=en
日本語
follow
/?Language=ja

follow
#

follow
Read the whitepaper
follow
/insights/value-based-healthcare/medical-communications-in-early-phase-product-development/
Read the whitepaper
follow
/insights/therapeutics/cell-and-gene-therapies/long-term-follow-up-studies-of-cell-and-gene-therapies/
Read the whitepaper
follow
/insights/transforming-trials/decentralised-and-hybrid-clinical-trials/practical-considerations-in-transitioning-to-dct/index.xml

follow

follow
The affordability hurdle for gene therapiesHow US payers perceive the value of advanced therapies.
follow
/insights/value-based-healthcare/the-affordability-hurdle-for-gene-therapies/

follow
Closing the evidence gapThe value of digital health technologies in supporting drug reimbursement decisions
follow
/insights/digital-disruption/closing-the-evidence-gap-the-value-of-digital-health-technologies-in-supporting-drug-reimburement-decisions/

follow
Glycomics: the future "sweet spot" in precision medicine diagnosticsThe rise of glycan biomarkers in therapeutic development.
follow
/insights/transforming-trials/glycomics/

follow
Parallel consultation from regulators and HTA bodies in EuropeOpportunities and challenges for drug developers.
follow
/insights/regulatory/eu-regulations/seeking-parallel-consultation-from-regulators-and-hta-bodies-in-EU/

follow

follow
Upcoming webinar: Reflections on paediatric assent8 November, 2021. Register now.
follow
/news-events/events/webinars/reflections-on-pediatric/index.xml
Upcoming webinar: ICON’s world children’s day15 November, 2021. Register now.
follow
/news-events/events/webinars/icons-world-childrens-day/
On-demand webinarsVisit our webinar channel to access other recent webinars.
follow
http://webinars.iconplc.com/

follow

follow
Market AccessExpertise in mission-critical pricing, market access, and reimbursement.
follow
/services/consulting/commercial-positioning-consulting/market-access/
Site & Patient Solutions Transforming recruitment through patient-centric trials and real-world, real-time data.
follow
/services/clinical-research-services/site-and-patient-recruitment/
BiotechICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.
follow
/sectors/biotech/
Functional ResourcingFrom recruitment of a single clinical professional to managing entire global functions.
follow
/services/functional-services-provision/careers/
Increasing Site and Patient ComplianceFIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.
follow
/innovation/firecrest/

follow
01 November 2021Diverse clinical research starts with the healthcare workforceDiversity initiatives are a hallmark of clinical research. From US Food and Drug Administration (FDA)-penned guidance and pharma initiatives to years of research showing that diverse trials improve outcomes, researchers have placed ample focus on the importance of diverse trial populations. Diversity is also essential in the clinical research workforce.Read more
follow
/insights/blog/2021/11/01/diverse-clinical-research-starts-with-the-healthcare-workforce
31 October 2021You attract what you are: How we can continue building a diverse, equal, and inclusive industryAs a woman of color (WOC) and first-born daughter of immigrants, my life has always had its set of challenges. My parents didn’t go to college – instead they each immigrated to America, from different countries, to pursue the “American Dream.” Growing up, my parents and I were learning a new language, culture, and lifestyle together.Read more
follow
/insights/blog/2021/10/31/you-attract-what-you-are-how-we-can-continue-building-a-diverse-equal-and-inclusive-industry
26 October 2021Data disruption: Navigating cardiovascular clinical trial adjudication during a respiratory pandemicCOVID-19 disrupted clinical trials across all indications. Patient enrolment, participation, data collection, and more was forced to adapt to the challenges of this virus.Read more
follow
/insights/blog/2021/10/26/data-disruption-navigating-cardiovascular-clinical-trial-adjudication-during-a-respiratory-pandemic
19 October 2021The impact of the COVID-19 pandemic on mental healthLearn how the ongoing state of the COVID-19 pandemic has affected the global mental health crisis. Read more
follow
/insights/blog/2021/10/19/the-impact-of-the-covid-19-pandemic-on-mental-health
01 October 2021ICON Joins UNICEF Corporate Vaccine AllianceICON is one of seven leading Irish companies that just endorsed an open letter urging fellow corporate leaders to join the UNICEF Corporate Vaccine Alliance. Read more
follow
/insights/blog/2021/10/01/icon-joins-unicef-corporate-vaccine-alliance
20 September 2021Rare disease patients and advocates drive change in public policyLearn how patient advocacy organisations and rare disease communities are driving change in US public policy to make safe and effective treatment options available to all patients.Read more
follow
/insights/blog/2021/09/20/rare-disease-patients-and-advocates-drive-change-in-public-policy
19 August 2021The promise of glycomics in medicineGlycomics has been a largely overlooked area of study. Nevertheless, it has the potential to have a significant impact on precision medicine and healthcare as a whole.Read more
follow
/insights/blog/2021/08/19/the-promise-of-glycomics-in-medicine
18 August 2021Battling HIV on many frontsDiscover how in-home services and a global development strategy can help us get closer to more effective treatments.Read more
follow
/insights/blog/2021/06/29/battling-hiv-on-many-fronts
17 August 2021Anatomic pathology in the digital ageThe development of new, innovative digital technologies has provided the tools to rethink the way we design and conduct clinical trials. One area that has been particularly impacted by this digital age is anatomical pathology. Read more
follow
/insights/blog/2021/06/28/anatomic-pathology-in-the-digital-age

follow
What’s happening in ICON
follow
/news-events/social-media/
Contact
follow
/contact/
About ICON
follow
/about/
Results & Reports
follow
https://investor.iconplc.com/financials-filings/annual-reports
Therapeutics
follow
/therapeutics/
Services
follow
/services/
Insights
follow
/insights/
Innovation
follow
/innovation/
Content Preferences
follow
/preferences/
Office locations
follow
/contact/global-office-locator/
Patients
follow
https://www.accellacare.com/
Volunteers
follow
https://study-volunteers.iconplc.com/
Investigators
follow
/investigators/
Jobs & Careers
follow
https://careers.iconplc.com/
Investors
follow
https://investor.iconplc.com/
Suppliers
follow
/icon-files/documents/ICON-Global-Supplier-Code-of-Conduct.pdf
Press Releases
follow
/news-events/press-releases/
Mediakit
follow
/news-events/mediakit/
Events
follow
/news-events/events/
Social Media Dashboard
follow
/news-events/social-media/
LinkedIn
follow
https://www.linkedin.com/company/icon-plc-2
Twitter
follow
https://twitter.com/ICONplc
Facebook
follow
https://www.facebook.com/icon.plc.profile
Youtube
follow
https://www.youtube.com/user/ICONPlc
Disclaimer
follow
/disclaimer/
Privacy
follow
/privacy/
Site Cookies
follow
/site-cookies/

follow
#
Contact us
follow
/contact/
Submit proposal request
follow
/contact/submit-rfp/
Update Email Preferences
follow
/preferences/
Global office locator
follow
/contact/global-office-locator/
ICON on social media
follow
/news-events/social-media/
Social signals
Title: 68 characters.
Description: 153 characters.
Domain Authority
Monthly pages viewed: 129378
Estimated worth: 59229 dollars

☷ Major sections

❀ Whois

We have developed a useful service for retrieve WhoIs information. "Whois" is a term that begins from the early days of the Internet, based on Unix operating system and university networks. On the Unix console, the command "whois" tries to determine the identity of the domain's registrant.

It is a means for Internet users to query various types of information such as IP addresses, user data and also domain data.

✦ SEO Report

Title / Meta tags

ICON plc | Clinical Research Organisation (CRO) for Drug Development

ICON is a global provider of outsourced development and commercialisation services to the pharmaceutical, biotechnology and medical device industries.

Image Analysis

A right example for an HTML image tag:

For SEO performance, you must write an alternative text. The alternative text must describe the image's content. Also, the alt tag is used for blind people. Their browsers tell them all about the description of the image.

Heading

Content Analysis

Code Analysis

We have not found hyphens (-) or underscores (_) in your URL. Google and expert domainers do not recommend buying domains with hyphens or underscores.

☛ Speed Analysis

When a visitor came to your website you can not fail. The user wants your page to load in a second. You know that it is difficult sometimes to display content in the first second but if the user has to wait too much time you can lose that user. If your page is too slow, you will lose a lot of web traffic. Your project URL load time is ms, it is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.iconplc.com is as follows:

A huge portion of visitors to your website are usually in rush and nobody is fond of waiting too much before your website loads its content. If your website is slow, you will lose a lot of visitors. Your homepage load time is ms is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.iconplc.com is as follows:

Speed:

Page Load Time: ms

⚐ Page Analysis

⚏ CSS Class names

no-js, wrapper, navbar bg-white fixed-top navbar-expand-xl, navbar-brand, header__logo, navbar-btn navbar-btn--search, icon-ui-search-loupe, navbar-btn navbar-btn--open, sr-only, navbar-btn__icon, collapse navbar-collapse, navbar-navs, navbar-btn navbar-btn--close, navbar-nav navbar-nav-primary mr-auto, nav-item dropdown, nav-link dropdown-toggle, dropdown-menu, navbar-btn navbar-btn--back, container-fluid container-fluid--xl, row, col-xl-3, section-overview--desktop, dropdown-item, section-overview--mobile, dropdown-item dropdown-item--with-image, image image--zoom-on-hover, img-fluid, h4, navbar-nav navbar-nav-secondary, nav-item, nav-link, nav-item-separator, nav-item nav-item--languages, nav-item d-none d-xl-block, navbar-revealer, navigation-backdrop fade, torso, content-box, carousel--promo, carousel__content, promo, promo__content, promo__image-overlay promo__image-overlay--blue, promo__image-container, promo__text-container, col-md-10 col-lg-7, lead, btn btn-white, promo__image-overlay promo__image-overlay--green, group bg-white, col-sm, block-link, container-full, card card--standard bg-white text-left, card-img-top rounded-0, card-body, card-title, card-text small, , text-picture text-picture--text-only text-left with-separator--top, text-picture__text, group content-visibility--auto contain-intrinsic-size--400, group__title, carousel--standard carousel--standard-1-3-3, block-link carousel__item, card card--overlapping-img card--overlapping-img-blue text-left, icon-ui-arrow-right, card card--overlapping-img card--overlapping-img-purple text-left, group group--with-carousel bg-light content-visibility--auto contain-intrinsic-size--800, col-md, card card--borderless card--news rounded-0, spotlight-system spotlight-system--flushed-right, spotlight-system__primary-circle bg-green-dark, spotlight-system__secondary-circle bg-yellow-green left, img-fluid rounded-circle, metatags, card-link card-link--with-arrow small, spotlight-system spotlight-system--flushed-left, spotlight-system__primary-circle bg-blue, spotlight-system__secondary-circle bg-gray-lighter right, spotlight-system__primary-circle bg-purple, spotlight-system__secondary-circle bg-blue-light right, spotlight-system__secondary-circle bg-blue-light left, spotlight-system__primary-circle bg-green, spotlight-system__primary-circle bg-gray-light, spotlight-system__secondary-circle right bg-green-bright, spotlight-system__secondary-circle bg-gray-lighter left, spotlight-system__primary-circle bg-yellow-green, spotlight-system__secondary-circle bg-green-dark right, spotlight-system__secondary-circle bg-green-bright right , content-bottom, group bg-green-light content-visibility--auto contain-intrinsic-size--650, social-feed, footer, footer__main-content, col-12 col-md-3, footer__logo, footer__nav--primary list-unstyled, external-link, col-6 col-md-2, footer__nav-title, footer__nav--secondary list-unstyled, col-12 col-md-2, list-social list-inline mb-0 float-md-right, list-inline-item, linkedin, fa fa-linkedin, twitter, fa fa-twitter, facebook, fa fa-facebook, youtube, fa fa-youtube-play, copyright, list-inline, contact-modal, icon-ui-speech-bubble, modal modal--contact fade, modal-dialog, close, modal-content, btn btn-blue btn--with-icon, icon-ui-envelope, icon-ui-document, icon-ui-preferences, icon-ui-pin, icon-ui-social-media, modal--contact__backdrop,

Ω HTTP Header Analysis

✪ Source Analysis

Your website is made from CSS files, images and javascript sources. We count all the files and their size. This is vital data about the performance of your website.